Drug intelligence / Profile preview

XC002

Development stage: Preclinical
Lead developer: XyloCor Therapeutics
Modality: Gene Addition/Replacement → Gene Therapies, Gene Editing → Gene Therapies, Gene Silencing → Gene Therapies
Administration: Intramyocardial

Overview

XC002 is a preclinical gene therapy candidate developed by XyloCor Therapeutics. It is intended for the treatment of cardiac tissue damage and is based on gene therapy technology exclusively licensed from Cornell University. This technology was developed by the company's co-founders, Ronald Crystal, MD, and Todd Rosengart, MD.

Beyond the preview

Go deeper on XC002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XC002.

Explore the full profile